CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLABO61

Testing for Alpha-1 Antitrypsin Deficiency

Defines BCBSOK reimbursement criteria for laboratory testing for alpha-1 antitrypsin deficiency (serum AAT quantification, phenotyping/proteotyping, and genotyping implications) and indicates which clinical scenarios and patient groups may be eligible for reimbursement. Applies to providers submitting claims to Blue Cross Blue Shield of Oklahoma.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyTesting for Alpha-1 Antitrypsin Deficiency

Policy CodePolicy CPCPLABO61

Change TypeNo material change

Effective DateNov 1, 2022

Next Review Date

Key ActionReview individual plan documents for coverage and prior authorization requirements before ordering AAT testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1.0policy version

Nov. 1, 2022plan start

Serum AAT & phenotypingtests addressed

ATS/ERS 2003guideline ref

Coverage Criteria for AAT Testing

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered clinical indications

Serum quantification of AAT protein and/or AAT phenotyping/proteotyping may be reimbursable when clinical indications match the following groups.

Reimbursable indications list: Symptomatic adults with emphysema, COPD, or asthma; individuals with persistent obstruction on pulmonary function tests without identifiable risk factors (e.g., cigarette smoking, occupational exposure); adults with necrotizing panniculitis; siblings of an individual with known alpha-1 antitrypsin (AAT) deficiency; individuals with bronchiectasis without evident etiology; individuals with anti-proteinase three-positive (C-ANCA) vasculitis; individuals with unexplained liver disease; other situations with strong clinical suspicion or discordant laboratory results where phenotyping/proteotyping is indicated.

List reflects policy reimbursable scenarios and supporting ATS/ERS guideline recommendations.

Phenotyping when genotype negative or discordant

Phenotyping/genotyping testing considerations

Phenotyping indication: Isoelectric focusing/phenotyping (Pi-typing) or proteotyping may be reimbursable when there is strong clinical suspicion based on symptoms and laboratory testing AND the individual has negative genotype testing for common variants or there are discordant results between AAT serum levels and proteotype.

Policy explicitly allows phenotyping when genotype is negative or results are discordant.

Testing for alpha-1 antitrypsin (AAT) deficiency is considered not reimbursable for scenarios that are not specifically listed among the policy's reimbursable clinical indications. The policy states that serum quantification and phenotyping/proteotyping may be reimbursable in defined clinical situations and that testing is not reimbursable in all other situations not enumerated in those lists. Claims lacking documentation of a listed indication are at risk for denial.

The policy references ATS/ERS recommendations when determining appropriateness of genetic/diagnostic testing. Per the cited guidance, Type C recommendations indicate testing is not recommended (should not be encouraged) and Type D recommendations indicate testing is discouraged.

Specifically, ATS/ERS guidance classifies adults with asthma in whom airflow obstruction is completely reversible as a Type C scenario for diagnostic testing — testing in this group is not recommended. The policy adopts these distinctions and aligns coverage decisions with those recommendations when applicable.

The ATS/ERS statement also identifies other situations that are not recommended (for example, pre-dispositional fetal testing and population screening of neonates, adolescents, or adults) and notes limited exceptions for population screening only under specific public-health conditions. Providers should follow these recommendations when determining the appropriateness of AAT genetic or diagnostic testing in adults with asthma and related clinical scenarios.

Provider Responsibilities & Billing Actions

Denial Risk

Denial Triggers

Claims may be denied if services are not supported by the clinical indications listed in this policy, if coding is incorrect, or if required documentation is not provided. Denials can result from submission of services that do not meet plan-specific lab management reimbursement criteria, use of invalid or non‑HIPAA code combinations, or failure to follow applicable provider contract or benefit document terms.

Claims subject to plan documents and provider contracts
Denial risk when clinical indications for testing are not met
Denial risk for improper coding or unsupported code combinations
Denial risk when plan-specific lab management criteria are not met

Prior Authorization

Plan-dependent Prior Authorization & Coverage

Certain lab management reimbursement criteria vary by product and may require review of the member's specific plan documents. Providers should verify coverage and any plan-dependent prior authorization or reimbursement rules before ordering tests.

Not all lab management requirements apply to every product — review Plan documents
Prior authorization or product-specific rules may apply

Documentation Required

Documentation Requirements

Providers must submit accurate, complete documentation to support medical necessity for billed services and be prepared to supply additional records upon request. Documentation should include clinical indication, relevant history, test results, and any prior testing that supports the need for the lab procedure.

Submit claims using valid HIPAA-approved code sets (CPT, HCPCS, ICD-10, NDC, etc.)
Include clinical notes, test results, and prior testing when applicable
Provide additional information promptly if requested by BCBSOK

Step Therapy

There are no step therapy requirements specified in this policy for laboratory testing; however, providers should confirm whether any product-specific utilization management applies via plan documents.

No step therapy specified in this policy
Check member's plan for any product-specific utilization management

Definitions and Laboratory Methods

AAT phenotyping / Pi-typing / proteotyping — methods and use

DefinitionLaboratory methods used to identify AAT protein variants, including isoelectric focusing (AAT phenotyping/Pi‑typing) and AAT proteotyping via liquid chromatography–tandem mass spectrometry (LC‑MS/MS).

PurposeTo detect Z and S alleles and other AAT protein variants when assessing for alpha‑1 antitrypsin deficiency.

When indicatedPerformed when serum AAT quantification and clinical picture suggest AAT deficiency, including cases with negative genotype for common variants or discordant serum level and genotype/proteotype results.

Common techniquesIsoelectric focusing for phenotyping; proteotyping (Pi‑typing) using LC‑MS/MS for allele‑specific protein identification.

Clinical roleUsed as a confirmatory test or to resolve discordant results between AAT serum levels and genotype; may be reimbursable in specified clinical scenarios (e.g., early‑onset emphysema, unexplained obstruction, necrotizing panniculitis, affected siblings, bronchiectasis, C‑ANCA vasculitis).

Background

Alpha-1 antitrypsin (AAT) deficiency is an inherited disorder that can lead to early-onset emphysema, chronic obstructive pulmonary disease (COPD), liver disease, and other manifestations such as necrotizing panniculitis. Diagnosis typically involves serum AAT quantification and, when indicated, phenotyping (isoelectric focusing) or proteotyping to identify Z, S, and other protein variants; genotyping may also be used for common variants. Clinical guidelines from ATS/ERS inform which patients should be tested and how results are interpreted.

Because AAT deficiency has variable clinical expression and implications for family members, the policy highlights testing in symptomatic individuals (for example, early-onset emphysema or unexplained persistent airflow obstruction), relatives of affected individuals, and selected other clinical situations where results would affect diagnosis or management.

OpenPayer

Testing for Alpha-1 Antitrypsin Deficiency

Coverage Criteria for AAT Testing

Coding Guidance

Provider Responsibilities & Billing Actions

Definitions and Laboratory Methods

Background